Long COVID has become a persistent national crisis that demands urgent attention, clear leadership, and a smart federal response. Millions of Americans still wake up with brain fog, crushing fatigue, and a host of baffling symptoms that medicine has not nailed down. This piece argues from a Republican viewpoint for renewed, focused investment and a return to the kind of bold public private partnerships that solved past health emergencies.
Long COVID is hitting hard and wide, affecting an estimated 18 million Americans. Patients describe severe cognitive problems, crushing fatigue, post exertional crash, irregular heartbeat, shortness of breath, strange blood clotting, ringing in the ears, and other neurological complaints. There is no reliable molecular test and no clear path from cause to cure, which leaves millions stuck in a medical limbo.
I spent a career treating deadly diseases in the Army, in academic medicine, and in public service, and I now see too many patients trapped by chronic illness after COVID. Their suffering is real, it is costly, and it is a national problem that requires a national response. We solved other once-mysterious diseases by setting priorities and funding research, and we can do the same here.
History offers a blueprint. When AIDS first appeared, the federal government, universities, and industry went after the problem with clarity and resources. That effort transformed HIV from a likely death sentence into a manageable, chronic condition for many patients. A similar commitment to discovery, diagnostics, and clinical trials could change the trajectory of Long COVID.
In 2020, Operation Warp Speed showed that public private teamwork can produce lifesaving medical advances quickly when leaders set ambitious goals and underwrite risk. Vaccines were developed at record speed to protect the vulnerable, and that success should inform our next moves. Now, President Trump and his team should direct the same urgency and creativity toward discovering effective treatments for Long COVID.
Unfortunately, the federal response has drifted. Research offices were closed and funding was scaled back as policymakers declared the emergency over. The CDC and NIH both stated that they would, “no longer waste billions of taxpayer dollars responding to a non-existent pandemic that Americans moved on from years ago.” That language ignores the reality on the ground and harms the millions still debilitated by lingering symptoms.
Cutting research at the moment cures were within reach was a costly mistake. Productivity losses and medical bills tied to Long COVID cost the country hundreds of billions every year, and we lost momentum just when clinical trials were about to accelerate. Some funding has been restored, but the overall effort remains underpowered and underfunded for the scale of the problem.
Secretary Robert F. Kennedy Jr. has signaled a renewed focus on chronic disease and committed to advancing biomarker discovery for Long COVID. That is the right direction and it needs real follow through. The NIH should prioritize diagnostics, support large coordinated studies, and push for translational work that moves discoveries from bench to bedside fast.
We do not need more politics; we need smart strategy and money behind it. Empower HHS to partner with industry and academic centers, fast track promising trials, and build clinical infrastructure so patients can join studies where they live. With leadership that treats Long COVID as the public health crisis it remains, we can give millions a real chance at recovery.
